Presenter: Natalie Gustafson, PharmD

Original Date: June 3, 2017

Traditional naltrexone has been used to help patients struggling with addiction to opiates or alcohol. However, for decades we have recognized that at lower dosages, aptly named Low Dose Naltrexone (LDN), we see an entirely different effect on the body. LDN has been shown to have a significant impact on improving gut function in various conditions from Crohn’s Disease to SIBO. Understanding its mechanisms of action and literature can help practitioners ascertain which SIBO patients might benefit from LDN as part of their treatment protocol.

Similarly, Low Dose Erythromycin (LDE) has become part of many SIBO management programs. Erythromycin has been used in gastroparesis caused by diabetes mellitus for many years, but as an antibiotic can had deleterious effects. This presentation covers the benefits of using lower dosing and its role in SIBO management, as well as when to use LDE, LDN or both.

1.0 Pharmacology CEUs approved by OBNM